214 related articles for article (PubMed ID: 9563673)
1. A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen.
Yen TC; Lin WY; Kao CH; Cheng KY; Wang SJ
Clin Otolaryngol Allied Sci; 1998 Feb; 23(1):82-6. PubMed ID: 9563673
[TBL] [Abstract][Full Text] [Related]
2. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma.
Lee JK; Hsieh JF; Tsai SC; Ho YJ; Sun SS; Kao CH
Ann Otol Rhinol Laryngol; 2001 Aug; 110(8):775-8. PubMed ID: 11510737
[TBL] [Abstract][Full Text] [Related]
3. Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck.
Ogawa T; Tsurusako Y; Kimura N; Nishioka S; Akagi H; Nishizaki K; Nishioka K; Rutka J
Acta Otolaryngol Suppl; 1999; 540():72-6. PubMed ID: 10445084
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours.
Banal A; Hacene K; Berthelot-Ruff E; Mahé E; Fontana X; Pichon MF
Tumour Biol; 2001; 22(1):27-35. PubMed ID: 11054024
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck.
Kandiloros D; Eleftheriadou A; Chalastras T; Kyriou L; Yiotakis I; Ferekidis E
Med Oncol; 2006; 23(4):463-70. PubMed ID: 17303904
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1.
Pradier O; Hille A; Schmiberger H; Hess CF
Cancer Radiother; 2002 Feb; 6(1):15-21. PubMed ID: 11899676
[TBL] [Abstract][Full Text] [Related]
8. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
9. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
[TBL] [Abstract][Full Text] [Related]
10. Serum SCCA, Cyfra 21-1, EGFR and Cyclin D1 levels in patients with oral squamous cell carcinoma.
Feng XY; Li JH; Li JZ; Han ZX; Xing RD
Int J Biol Markers; 2010; 25(2):93-8. PubMed ID: 20586028
[TBL] [Abstract][Full Text] [Related]
11. [Investigation of the usefulness of CYFRA 21-1 as a tumor marker in squamous cell carcinomas of the head and neck].
Sano K; Kataoka S; Katoh T; Kawauchi H; Morikawa S
Nihon Jibiinkoka Gakkai Kaiho; 1997 Jul; 100(7):790-7. PubMed ID: 9277101
[TBL] [Abstract][Full Text] [Related]
12. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.
Kuropkat C; Lippert BM; Werner JA
Oncology; 2002; 63(3):280-5. PubMed ID: 12381908
[TBL] [Abstract][Full Text] [Related]
13. [Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck].
González Sánchez E; López-Ríos Velasco J; Calvo Boizas E; García-Talavera Fernández JR; Martín Ro-dríguez M; Muñoz Herrera A; Del Cañizo Alvarez A
Acta Otorrinolaringol Esp; 1999 Mar; 50(2):85-9. PubMed ID: 10217679
[TBL] [Abstract][Full Text] [Related]
14. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.
Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A
Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778
[TBL] [Abstract][Full Text] [Related]
15. Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN).
Niemann AM; Goeroegh T; Gottschlich S; Lippert BM; Werner JA
Anticancer Res; 1997; 17(4B):2859-60. PubMed ID: 9329547
[TBL] [Abstract][Full Text] [Related]
16. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH
J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374
[TBL] [Abstract][Full Text] [Related]
17. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma.
Lin WY; Yen TC; Cheng KY; Wang SJ
Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997
[TBL] [Abstract][Full Text] [Related]
18. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
[TBL] [Abstract][Full Text] [Related]
19. Study of cyfra 21-1, a tumor marker, in head and neck squamous cell carcinoma.
Céruse P; Rabilloud M; Charrié A; Dubreuil C; Disant F
Ann Otol Rhinol Laryngol; 2005 Oct; 114(10):768-76. PubMed ID: 16285267
[TBL] [Abstract][Full Text] [Related]
20. CYFRA 21-1: a suitable tumor marker in patients with head and neck cutaneous squamous cell carcinoma?
Rudhart SA; Schultz JD; Gehrt F; Pavel FL; Birk R; Hoch M; Stuck BA; Hoch S
Eur Arch Otorhinolaryngol; 2019 Dec; 276(12):3467-3475. PubMed ID: 31482332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
